Global Nipah Virus (NiV) Infection Testing Industry Eyes Noteworthy 5.2% Growth, Aiming for US$ 3,277.49 Million by 2033 | FMI

The Global Nipah Virus (Niv) Infection Testing Industry is poised for substantial growth during the forecast period from 2023 to 2033, with a projected Compound Annual Growth Rate (CAGR) of 5.2%, according to the latest analysis by Future Market Insights. By 2033, the market is anticipated to reach a staggering valuation of US$ 3,277.49 million.

Nipah virus, a zoonotic virus with the potential to cause severe encephalitis and fatal outcomes in humans, has seen an increasing prevalence worldwide, contributing to the surge in demand for advanced NiV infection testing solutions.

In 2023, the market size for Nipah virus (NiV) infection testing is estimated to be US$ 1,974.17 million, with a forecasted growth to US$ 3,277.49 million by 2033, showcasing a robust CAGR of 5.2%. This growth can be attributed to the imperative need for early detection and control of NiV infection outbreaks.

Request Sample Copy of Report
https://www.futuremarketinsights.com/reports/sample/rep-gb-16756

The Global Nipah Virus (NiV) Infection Testing Industry has become an important part of public health monitoring and disease surveillance for governments, healthcare providers, and the medical community. The NiV infection testing market has seen several advancements over the years. The latest developments include improved nucleic acid-based tests that offer higher accuracy and faster results. This has helped reduce the risk of false positives and enabled healthcare providers to identify infected individuals more quickly.

In addition, the development of point-of-care testing devices for NiV infections has enabled healthcare providers to diagnose patients in remote areas without access to laboratory facilities. This has helped in the early detection and treatment of infected individuals in areas with limited healthcare resources. Furthermore, Asia Pacific along with Middle East and Africa are the largest contributors to the Nipah virus (NiV) infection testing market.

Key Takeaways from the Global Nipah Virus (NiV) Infection Testing Industry Study

• The Global Nipah Virus (NiV) Infection Testing Industry is expected to grow at a value of 5.2% CAGR in the forecast period 2023 to 2033
• By end user, hospitals are expected to possess 40% market share for Nipah virus (NiV) infection testing market in 2023.
• Asia Pacific is expected to possess 45% market share for Nipah virus (NiV) infection testing market in 2023.
• Middle East and Africa is expected to possess 39% market share for Nipah virus (NiV) infection testing market in 2023.

“The NiV infection testing market provides several benefits to the medical community and the general public. It enables healthcare providers to identify and treat infected individuals quickly and accurately. This helps reduce the spread of the virus and possible complications of the infection.” states an FMI analyst

Grab Your Report on Discount Before It’s Gone!
https://www.futuremarketinsights.com/request-discount/rep-gb-16756

Global Nipah Virus (NiV) Infection Testing Industry Competitive Landscape

Key players in the Nipah virus (NiV) infection testing market are Aurobindo, Minapharm, Roche, Lupin Ltd, Siegfried, Vivacure, Starlake Bioscience, Xaretto, Liferiver, MyBioSource, Krishgen Biosystems

• Aurobindo has developed a rapid diagnostic test for NiV, allowing clinicians to quickly detect the presence of the virus. Additionally, Aurobindo has used its expertise in the field of immunoassay and ELISA development to create an antibody test for NiV.
• In July 2020, Roche launched the cobas® NiV/HEV Assay. This test is a qualitative in-vitro diagnostic assay that detects NiV and HEV nucleic acid from human specimens and provides results in just under two hours.

Key Segments Profiled in the Nipah Virus (NiV) Infection Testing Industry Survey

Test Type:

• RT PCR based kits
• ELISA Kits

End User:

• Hospitals
• Research Labs
• Diagnostic Centres

Request Your Customized Report Now!
https://www.futuremarketinsights.com/customization-available/rep-gb-16756

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube